Over the past 25 years, we’ve made a number of critical strategic investments. These multi-million pound, long-term investments in people, resources and technology have helped transform key areas of science.
These facilities allow science to happen at a scale or speed that was previously not possible. They give researchers the cutting-edge technology needed to transform our understanding – from high throughput sequencing in genomics to the study of protein structures at sub-atomic resolution. This helps researchers make new discoveries, and can also open up entirely new avenues of science for exploration.
Our large-scale strategic investment has so far been focused in the UK. It's helped to ensure the UK stays as a key player in global science and the data is made available to researchers anywhere in the world:
The Wellcome Sanger Institute(opens in a new tab) in Hinxton, Cambridgeshire was established in 1993 to collaborate on the Human Genome Project – the sequencing of the first human genome. We have continued to fund Sanger and it has grown into a world-leading institute in human genomics research.
Diamond Light Source(opens in a new tab) near Didcot, Oxfordshire is the UK’s national synchrotron. We partnered with the UK government, through the Science and Technology Facilities Council, to set up this ambitious project in 1998. It's the largest scientific facility in the UK and provides state-of-the-art facilities for life and physical sciences. It is used by thousands of researchers from academia and industry every year.
UK Biobank(opens in a new tab) is a powerful clinical research resource. Samples and data from half a million people in the UK aged between 40 and 69 are collected at regular intervals. That gives an extraordinary insight into the whole UK population and how different genetic and lifestyle factors contribute to disease and life expectancy.
Stevenage Bioscience Catalyst(opens in a new tab) is a partnership between Wellcome, the UK government, GlaxoSmithKline (GSK), the East of England Development Agency and the Technology Strategy Board, to develop a bioscience park next to GSK's research and development facilities in Stevenage, Hertfordshire. The park is designed to encourage innovation and speed up product development.